Review



sequencher 5.0 sequence analysis software demo  (Gene Codes Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Gene Codes Inc sequencher 5.0 sequence analysis software demo
    Sequencher 5.0 Sequence Analysis Software Demo, supplied by Gene Codes Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sequencher+5%2E0+sequence+analysis+software+demo/sequencher+software/pmc10506908-75-22-28
    Average 90 stars, based on 1 article reviews
    sequencher 5.0 sequence analysis software demo - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Sequencing:

    Article Title: DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship?
    Article Snippet: The POLG sequences were aligned with a reference sequence NG_008218.1 (available in the National Center for Biotechnology Information [NCBI] database) using the Sequencher 5.0 sequence analysis software demo (Gene Codes Corporation, Ann Arbor, MI, USA).

    Article Title: Novel non-neutral mitochondrial DNA mutations found in childhood acute lymphoblastic leukemia.
    Article Snippet: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.. Please cite this article as doi: 10.1111/cge.13100 This article is protected by copyright.. All rights reserved.

    Article Title: DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship?
    Article Snippet: The POLG sequences were aligned with a reference sequence NG_008218.1 (available in the National Center for Biotechnology Information [NCBI] database) using the Sequencher 5.0 sequence analysis software demo (Gene Codes Corporation, Ann Arbor, MI, USA).Ta bl e 1. co n ti n u ed Pa ti en t PO LG 1 va ri an t A LT (U /l ) C TC A E g ra d e (A LT ) D ay s af te r d g fo r h ig h es t A LT va lu e B il (μ m ol /l ) C TC A E g ra d e (B il) D ay s af te r d g fo r h ig h es t B il va lu e M eM P (h ig h es t, n m ol / m m ol H g b ) M eM P (l ow es t, n m ol / m m ol H g b ) M eM P (m ea n , n m ol / m m ol H g b ) Tr ea tm en t ri sk g ro up SA E 26 p .Q 12 36 H 61 5 3 61 6 35 1 60 9 90 72 11 44 43 50 SR 27 30 3 3 48 3 26 1 63 1 32 90 1 16 88 14 54 6 SR O st eo n ec ro si s 28 p .Q 12 36 H 21 4 3 90 8 17 0 90 0 85 44 45 3 53 16 IR A n ap h yl ax is , fu n g al in fe ct io n 29 85 6 4 90 2 15 0 47 0 25 12 5 < 60 69 83 SR 30 p .Q 12 36 H 53 5 3 90 1 22 0 89 2 30 65 8 < 60 98 43 IR 31 p .G 51 7V 20 94 4 59 5 17 0 59 6 45 14 < 60 22 30 SR 32 27 6 3 89 7 22 0 11 9 10 78 0 < 60 29 77 SR O st eo n ec ro si s, p ar al ys is 33 64 1 23 2 N A N A N A 18 22 7 < 60 17 96 IR In te n si ve ca re 34 p .E 11 43 G 10 3 1 36 3 46 2 36 9 25 19 3 < 60 94 13 SR O st eo n ec ro si s, p ar al ys is A LT se ru m al an in e am in o tr an sf er as e, Bi lb ili ru b in , CT CA E co m m o n te rm in o lo g y cr it er ia fo r ad ve rs e ev en ts ,d g d ia g n o si s, H R h ig h -r is k tr ea tm en t g ro u p ,I R in te rm ed ia te ri sk tr ea tm en t g ro u p ,M eM P m et h yl at ed 6- m er ca p to p u ri n e m et ab o lit es ,N A n o t av ai la b le ,P RE S p o st er io r re ve rs ib le en ce p h al o p at h y sy n d ro m e, SA E se ve re ad ve rs e ev en t, SR st an d ar d ri sk tr ea tm en t g ro u p . The Pharmacogenomics Journal RESULTS Patients with severe hepatotoxicity during maintenance therapy Three patients (3/34; 9%) showed grade 4 ALT levels (20 times above the upper normal limit) based on the Common Terminology Criteria for Adverse Events v5.0 (CTCAE) [19] with peaks at 856, 1145, and 2094 (U/l) (Table 1).

    Software:

    Article Title: DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship?
    Article Snippet: The POLG sequences were aligned with a reference sequence NG_008218.1 (available in the National Center for Biotechnology Information [NCBI] database) using the Sequencher 5.0 sequence analysis software demo (Gene Codes Corporation, Ann Arbor, MI, USA).

    Article Title: Novel non-neutral mitochondrial DNA mutations found in childhood acute lymphoblastic leukemia.
    Article Snippet: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.. Please cite this article as doi: 10.1111/cge.13100 This article is protected by copyright.. All rights reserved.

    Article Title: DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship?
    Article Snippet: The POLG sequences were aligned with a reference sequence NG_008218.1 (available in the National Center for Biotechnology Information [NCBI] database) using the Sequencher 5.0 sequence analysis software demo (Gene Codes Corporation, Ann Arbor, MI, USA).Ta bl e 1. co n ti n u ed Pa ti en t PO LG 1 va ri an t A LT (U /l ) C TC A E g ra d e (A LT ) D ay s af te r d g fo r h ig h es t A LT va lu e B il (μ m ol /l ) C TC A E g ra d e (B il) D ay s af te r d g fo r h ig h es t B il va lu e M eM P (h ig h es t, n m ol / m m ol H g b ) M eM P (l ow es t, n m ol / m m ol H g b ) M eM P (m ea n , n m ol / m m ol H g b ) Tr ea tm en t ri sk g ro up SA E 26 p .Q 12 36 H 61 5 3 61 6 35 1 60 9 90 72 11 44 43 50 SR 27 30 3 3 48 3 26 1 63 1 32 90 1 16 88 14 54 6 SR O st eo n ec ro si s 28 p .Q 12 36 H 21 4 3 90 8 17 0 90 0 85 44 45 3 53 16 IR A n ap h yl ax is , fu n g al in fe ct io n 29 85 6 4 90 2 15 0 47 0 25 12 5 < 60 69 83 SR 30 p .Q 12 36 H 53 5 3 90 1 22 0 89 2 30 65 8 < 60 98 43 IR 31 p .G 51 7V 20 94 4 59 5 17 0 59 6 45 14 < 60 22 30 SR 32 27 6 3 89 7 22 0 11 9 10 78 0 < 60 29 77 SR O st eo n ec ro si s, p ar al ys is 33 64 1 23 2 N A N A N A 18 22 7 < 60 17 96 IR In te n si ve ca re 34 p .E 11 43 G 10 3 1 36 3 46 2 36 9 25 19 3 < 60 94 13 SR O st eo n ec ro si s, p ar al ys is A LT se ru m al an in e am in o tr an sf er as e, Bi lb ili ru b in , CT CA E co m m o n te rm in o lo g y cr it er ia fo r ad ve rs e ev en ts ,d g d ia g n o si s, H R h ig h -r is k tr ea tm en t g ro u p ,I R in te rm ed ia te ri sk tr ea tm en t g ro u p ,M eM P m et h yl at ed 6- m er ca p to p u ri n e m et ab o lit es ,N A n o t av ai la b le ,P RE S p o st er io r re ve rs ib le en ce p h al o p at h y sy n d ro m e, SA E se ve re ad ve rs e ev en t, SR st an d ar d ri sk tr ea tm en t g ro u p . The Pharmacogenomics Journal RESULTS Patients with severe hepatotoxicity during maintenance therapy Three patients (3/34; 9%) showed grade 4 ALT levels (20 times above the upper normal limit) based on the Common Terminology Criteria for Adverse Events v5.0 (CTCAE) [19] with peaks at 856, 1145, and 2094 (U/l) (Table 1).



    Similar Products

    sequencher 5.0 sequence analysis software demo  (Gene Codes Inc)
    90
    Gene Codes Inc sequencher 5.0 sequence analysis software demo
    Sequencher 5.0 Sequence Analysis Software Demo, supplied by Gene Codes Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sequencher+5%2E0+sequence+analysis+software+demo/sequencher+software/pmc10506908-75-22-28
    Average 90 stars, based on 1 article reviews
    sequencher 5.0 sequence analysis software demo - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results